Business Wire

WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe

Share

EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations.

WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform.

The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%.

WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose.

“Providing access to Tesla Superchargers through the WEX platform is a win for drivers and fleet managers,” said Jay Dearborn, WEX’s chief operating officer, International. “Drivers get effortless, reliable access to one of Europe’s largest fast-charging networks. Fleet managers gain the clarity and control they count on from WEX, with unified payments, smarter route planning, and more predictable charging costs. This update helps make EV operations simpler, more transparent, and ready for what’s next.”

How it works

Drivers have two flexible options to access Tesla Superchargers:

Via EV Driver by WEX: Select a Tesla Supercharger location and compare pricing with nearby alternatives. After selecting a connector, start a charging session from the app.

Via Tesla app: Add your WEX EV charge card as a payment method in the Tesla app and start a charging session there. Payments and billing remain in one place and are processed by WEX. Tesla drivers benefit from plug-and-charge convenience.

The integration is live now across all Tesla Supercharger locations for both Tesla and non-Tesla vehicles.

For more information on WEX EV charging options, please visit the WEX EV Solutions website.

About WEX

WEX (NYSE: WEX) is the global commerce platform that simplifies the business of running a business. WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility, and paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. For more information, please visit www.wexinc.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, statements regarding WEX’s announced integration with the Tesla Supercharger network. Any statements in this press release that are not statements of historical facts are forward-looking statements. When used in this press release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “positions,” “confidence,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. Forward-looking statements relate to our future plans, objectives, expectations, and intentions and are not historical facts and accordingly involve known and unknown risks and uncertainties and other factors that may cause the actual results or performance to be materially different from future results or performance expressed or implied by these forward-looking statements, including the ability of the Company, its partners and its customers to realize the expected benefits from WEX’s integration with the Tesla Supercharger network; as well as other risks and uncertainties identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 20, 2025, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 1, 2025 and subsequent filings with the Securities and Exchange Commission. The forward-looking statements speak only as of the date of this press release and undue reliance should not be placed on these statements. The Company disclaims any obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117575835/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release

Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release

Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye